153 related articles for article (PubMed ID: 2033524)
1. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats.
Neisewander JL; Lucki I; McGonigle P
J Pharmacol Exp Ther; 1991 May; 257(2):850-60. PubMed ID: 2033524
[TBL] [Abstract][Full Text] [Related]
2. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.
Moro H; Sato H; Ida I; Oshima A; Sakurai N; Shihara N; Horikawa Y; Mikuni M
Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
4. Anatomical localization of SKF-38393-induced behaviors in rats using the irreversible monoamine receptor antagonist EEDQ.
Neisewander JL; Ong A; McGonigle P
Synapse; 1995 Feb; 19(2):134-43. PubMed ID: 7725242
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
7. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
8. Repeated intra-ventral tegmental area administration of SKF-38393 induces behavioral and neurochemical sensitization to a subsequent cocaine challenge.
Pierce RC; Born B; Adams M; Kalivas PW
J Pharmacol Exp Ther; 1996 Jul; 278(1):384-92. PubMed ID: 8764374
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
Subramaniam S; Lucki I; McGonigle P
Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
[TBL] [Abstract][Full Text] [Related]
10. D1 receptor stimulation inhibits dopamine cell activity after reserpine treatment but not after chronic SCH 23390: an effect blocked by N-methyl-D-aspartate antagonists.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1992 Jan; 260(1):409-16. PubMed ID: 1530977
[TBL] [Abstract][Full Text] [Related]
11. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.
Neisewander JL; Lucki I; McGonigle P
Brain Res; 1991 Aug; 558(1):27-35. PubMed ID: 1933381
[TBL] [Abstract][Full Text] [Related]
12. Neurochemical correlates of behavioral sensitization following repeated apomorphine treatment: assessment of the role of D1 dopamine receptor stimulation.
Rowlett JK; Mattingly BA; Bardo MT
Synapse; 1993 Jun; 14(2):160-8. PubMed ID: 8332946
[TBL] [Abstract][Full Text] [Related]
13. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
Schmidt HD; Pierce RC
Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
[TBL] [Abstract][Full Text] [Related]
14. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L
Synapse; 1990; 5(2):113-9. PubMed ID: 2137942
[TBL] [Abstract][Full Text] [Related]
15. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
Jiang LH; Kasser RJ; Altar CA; Wang RY
J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
[TBL] [Abstract][Full Text] [Related]
16. Super-stereotypy I: enhancement of a complex movement sequence by systemic dopamine D1 agonists.
Berridge KC; Aldridge JW
Synapse; 2000 Sep; 37(3):194-204. PubMed ID: 10881041
[TBL] [Abstract][Full Text] [Related]
17. Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist.
Cory-Slechta DA; Widzowski DV; Newland MC
J Pharmacol Exp Ther; 1989 Sep; 250(3):800-8. PubMed ID: 2789282
[TBL] [Abstract][Full Text] [Related]
18. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
19. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
[TBL] [Abstract][Full Text] [Related]
20. Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
Merchant KM; Bush LG; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1990 Nov; 255(2):775-80. PubMed ID: 2147039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
